Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor
Sponsored by Fred Hutchinson Cancer Center
About this trial
Last updated 17 years ago
Study ID
FHCRC 0800.01
Status
Completed
Type
Interventional
Phase
Phase 1/Phase 2
Placebo
No
Accepting
Up to 55 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 18 years ago
What is this trial about?
A single arm dose optimization study in which all patients are given a fixed dose of
Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy
is escalated or de-escalated dependent upon engraftment and toxicity.
What are the participation requirements?
Inclusion Criteria
- Life-threatening marrow failure of nonmalignant etiology;
- failure to respond to the best available immunosuppressive treatment;
- lack of a HLA-identical family member
Exclusion Criteria
- Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure;
- HIV seropositive patients;
- clonal abnormalities or myelodysplastic syndrome;